Douglas L Arnold
#113,277
Most Influential Person Now
Researcher
Douglas L Arnold's AcademicInfluence.com Rankings
Douglas L Arnoldmathematics Degrees
Mathematics
#5549
World Rank
#7803
Historical Rank
Applied Mathematics
#144
World Rank
#161
Historical Rank
Measure Theory
#791
World Rank
#1051
Historical Rank

Download Badge
Mathematics
Douglas L Arnold's Degrees
- PhD Mathematics University of Chicago
Why Is Douglas L Arnold Influential?
(Suggest an Edit or Addition)Douglas L Arnold's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. (2012) (1465)
- B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (2008) (1332)
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2017) (1170)
- Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis (2017) (1107)
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012) (1044)
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (2012) (1037)
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018) (559)
- Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy (1996) (527)
- Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. (2001) (516)
- Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. (1998) (513)
- Imaging axonal damage of normal-appearing white matter in multiple sclerosis. (1998) (505)
- Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial (2008) (476)
- Reversible decreases in N‐acetylaspartate after acute brain injury (1995) (462)
- Mesial temporal damage in temporal lobe epilepsy: a volumetric MRI study of the hippocampus, amygdala and parahippocampal region. (2003) (444)
- Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging (2013) (335)
- Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques (1992) (334)
- Chemical pathology of acute demyelinating lesions and its correlation with disability (1995) (311)
- Exploring Uncertainty Measures in Deep Networks for Multiple Sclerosis Lesion Detection and Segmentation (2018) (310)
- Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. (2000) (310)
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study (2014) (306)
- Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease (1990) (306)
- Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. (2006) (290)
- Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study (2011) (288)
- Incidence of acquired demyelination of the CNS in Canadian children (2009) (283)
- Neuroimaging evidence of progressive neuronal loss and dysfunction in temporal lobe epilepsy (1999) (278)
- Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis (2014) (251)
- Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy (1997) (248)
- Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial (2016) (247)
- Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: A series of 100 patients (1997) (242)
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. (2015) (237)
- A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease (2011) (234)
- Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images (1994) (232)
- Robust Rician noise estimation for MR images (2010) (225)
- Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis (1991) (206)
- Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis (1994) (203)
- The relationship between diffuse axonal damage and fatigue in multiple sclerosis. (2004) (202)
- Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations (2013) (199)
- Aerobic conditioning in patients with mitochondrial myopathies: Physiological, biochemical, and genetic effects (2001) (191)
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension (2018) (190)
- Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. (1998) (190)
- In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. (1999) (187)
- EXCESSIVE INTRACELLULAR ACIDOSIS OF SKELETAL MUSCLE ON EXERCISE IN A PATIENT WITH A POST-VIRAL EXHAUSTION/FATIGUE SYNDROME A 31P Nuclear Magnetic Resonance Study (1984) (186)
- Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo (1994) (184)
- Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. (2002) (183)
- Recovery of N‐acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy (1998) (180)
- Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability. (2002) (175)
- Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. (1996) (174)
- Alemtuzumab CARE-MS II 5-year follow-up (2017) (174)
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis (2014) (173)
- Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. (2000) (171)
- Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? (2012) (169)
- Texture analysis and morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra‐temporal partial epilepsy (2001) (168)
- A proton magnetic resonance spectroscopy study of focal epilepsy in humans (1990) (168)
- Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions (2008) (168)
- Relating neocortical pathology to disability progression in multiple sclerosis using MRI (2004) (167)
- Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b (2001) (166)
- Short‐term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders (1995) (165)
- High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. (2015) (164)
- Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. (1999) (164)
- MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study (2011) (162)
- Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. (2007) (158)
- Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. (2019) (151)
- Evaluating intensity normalization on MRIs of human brain with multiple sclerosis (2011) (148)
- Magnetic resonance spectroscopy and imaging of the thalamus in idiopathic generalized epilepsy. (2003) (139)
- IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event (2006) (139)
- Automated detection of focal cortical dysplasia lesions using computational models of their MRI characteristics and texture analysis (2003) (138)
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials (2020) (137)
- Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes (2019) (137)
- Effects of aerobic training in patients with mitochondrial myopathies (1998) (133)
- Alemtuzumab CARE-MS I 5-year follow-up (2017) (132)
- Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial (2016) (132)
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study (2016) (130)
- 2010 McDonald criteria for diagnosing pediatric multiple sclerosis (2012) (130)
- Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation (2013) (130)
- MRI correlates of cognitive impairment in childhood-onset multiple sclerosis. (2011) (129)
- In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondria1 disease (1991) (129)
- Trial of Fingolimod versus Interferon Beta‐1a in Pediatric Multiple Sclerosis (2018) (127)
- Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease (1993) (126)
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial (2016) (125)
- Guidelines for using proton MR spectroscopy in multicenter clinical MS studies (2007) (123)
- T2 Relaxometry Can Lateralize Mesial Temporal Lobe Epilepsy in Patients with Normal MRI (2000) (121)
- Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors (2007) (120)
- MR image-guided P-31 MR spectroscopy in the evaluation of brain tumor treatment. (1987) (117)
- Neuroimaging in multiple sclerosis. (1995) (117)
- Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading (1990) (116)
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial (2019) (113)
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial (2019) (112)
- High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS (2017) (112)
- Quantitative magnetization transfer and myelin water imaging of the evolution of acute multiple sclerosis lesions (2010) (111)
- 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. (2005) (110)
- Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy (2000) (109)
- Magnetization transfer can predict clinical evolution in patients with multiple sclerosis (2002) (108)
- Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree (2000) (106)
- Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion (2007) (100)
- Regional variations in normal brain shown by quantitative magnetization transfer imaging (2004) (99)
- Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? (1999) (98)
- Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE (2015) (97)
- Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis (2019) (97)
- Is ictal recording mandatory in temporal lobe epilepsy? Not when the interictal electroencephalogram and hippocampal atrophy coincide. (2000) (96)
- Trimmed-Likelihood Estimation for Focal Lesions and Tissue Segmentation in Multisequence MRI for Multiple Sclerosis (2011) (95)
- Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations (2015) (93)
- Neuronal metabolic dysfunction in patients with cortical developmental malformations (1998) (93)
- Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth (2014) (93)
- Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions (2018) (92)
- MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group (2002) (91)
- Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis (2006) (90)
- A prospective, randomized, placebo‐controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results (2003) (89)
- MRI in the diagnosis and management of multiple sclerosis (2002) (88)
- Clinically feasible MTR is sensitive to cortical demyelination in MS (2013) (87)
- Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
- Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis (2003) (87)
- Magnetic Resonance Spectroscopy Guided Brain Tumor Resection: Differentiation Between Recurrent Glioma and Radiation Change in Two Diagnostically Difficult Cases (1998) (87)
- Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases (2006) (86)
- Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis (2010) (84)
- Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. (2005) (83)
- Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial (2019) (83)
- Short‐term aerobic training response in chronic myopathies (1999) (80)
- Axonal dysfunction and disability in a relapse of multiple sclerosis: Longitudinal study of a patient (1997) (80)
- Lesion distribution in children with clinically isolated syndromes (2008) (80)
- EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis (2006) (80)
- Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change (2010) (79)
- Multiple Sclerosis Lesion Segmentation Using an Automatic Multimodal Graph Cuts (2009) (79)
- Function and organization in dysgenic cortex. Case report. (1997) (78)
- Mental fatigue alters the pattern and increases the volume of cerebral activation required for a motor task in multiple sclerosis patients with fatigue (2008) (78)
- In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging (1998) (77)
- Proton Magnetic Resonance Spectroscopic Imaging in Patients with Extratemporal Epilepsy (1998) (75)
- Magnetic resonance spectroscopy: imaging axonal damage in MS (1999) (75)
- ADP Recovery After a Brief Ischemic Exercise in Normal and Diseased Human Muscle — a 31P MRS Study (1996) (74)
- Cerebral dysgenesis and lactic acidemia: an MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency. (1994) (74)
- Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study (2016) (73)
- Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data (2021) (72)
- Regional brain atrophy in children with multiple sclerosis (2011) (72)
- Proton magnetic resonance spectroscopic imaging for discrimination of absence and complex partial seizures (1997) (72)
- Computational Models of MRI Characteristics of Focal Cortical Dysplasia Improve Lesion Detection (2002) (70)
- Morphometric MRI Analysis of the Parahippocampal Region in Temporal Lobe Epilepsy (2000) (70)
- Serum neurofilament light as a biomarker in progressive multiple sclerosis (2020) (70)
- Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency (1996) (70)
- Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. (2000) (70)
- Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis☆ (2013) (69)
- A mitochondrial encephalomyopathy A combined 31P magnetic resonance and biochemical investigation (1985) (69)
- Rotation-invariant multi-contrast non-local means for MS lesion segmentation (2015) (69)
- Examination of the energetics of aging skeletal muscle using nuclear magnetic resonance. (1984) (68)
- Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies (2014) (68)
- Statistical power and prediction accuracy in multisite resting-state fMRI connectivity (2017) (68)
- Temporally Consistent Probabilistic Detection of New Multiple Sclerosis Lesions in Brain MRI (2013) (67)
- MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. (2018) (66)
- Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study (2014) (65)
- Phase III dose‐comparison study of glatiramer acetate for multiple sclerosis (2011) (64)
- Quantitative Determination of Regional Lesion Volume and Distribution in Children and Adults with Relapsing-Remitting Multiple Sclerosis (2014) (64)
- Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. (1999) (63)
- Changes in cognitive performance over a 1-year period in children and adolescents with multiple sclerosis. (2013) (62)
- Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study (2015) (62)
- Entorhinal Cortex MRI Assessment in Temporal, Extratemporal, and Idiopathic Generalized Epilepsy (2003) (61)
- The role of edema and demyelination in chronic T1 black holes: A quantitative magnetization transfer study (2005) (61)
- Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis (2013) (61)
- Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis (2015) (61)
- Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial (2020) (60)
- Five years of ocrelizumab in relapsing multiple sclerosis (2020) (59)
- Effect of dimethyl fumarate on lymphocytes in RRMS (2019) (59)
- Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study (2014) (59)
- Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients (2015) (57)
- Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study (2013) (57)
- Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. (1985) (57)
- Epitope spreading as an early pathogenic event in pediatric multiple sclerosis (2014) (56)
- The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. (1998) (56)
- Mitochondrial disease. Pulmonary function, exercise performance, and blood lactate levels. (1995) (56)
- Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution (2001) (56)
- Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients (2005) (55)
- Proton magnetic resonance spectroscopic imaging suggests progressive neuronal damage in human temporal lobe epilepsy. (2002) (55)
- Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter (2006) (55)
- White matter integrity and math performance in pediatric multiple sclerosis: a diffusion tensor imaging study (2011) (54)
- Imaging of axonal damage in vivo in Rasmussen's syndrome. (1995) (54)
- Ca2+-ATPase deficiency in a patient with an exertional muscle pain syndrome. (1988) (54)
- Magnetic resonance spectroscopy in Niemann-Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin. (1994) (54)
- Automated quality control of brain MR images (2008) (53)
- Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis (2003) (53)
- Impairment of muscle mitochondrial oxidative metabolism in McArdle's disease (1996) (53)
- Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial (2016) (52)
- Spatial Extent of Neuronal Metabolic Dysfunction Measured by Proton MR Spectroscopic Imaging in Patients with Localization‐Related Epilepsy (2000) (52)
- Automated Estimation of Brain Volume in Multiple Sclerosis with BICCR (2001) (51)
- Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. (2009) (50)
- Significance of mesial temporal atrophy in relation to intracranial ictal and interictal stereo EEG abnormalities. (1996) (50)
- Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI Using Conditional Random Fields (2012) (50)
- Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study (2018) (50)
- Predicting surgical outcome in temporal lobe epilepsy patients using MRI and MRSI (2002) (49)
- Proton magnetic resonance spectroscopic images and MRI volumetric studies for lateralization of temporal lobe epilepsy. (1995) (49)
- Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging (2006) (48)
- Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials (2014) (48)
- Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis (2019) (47)
- Diffusion tensor imaging and cognitive speed in children with multiple sclerosis (2011) (47)
- Characterization of astrocytomas, meningiomas, and pituitary adenomas by phosphorus magnetic resonance spectroscopy. (1991) (47)
- Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: Consensus report of the white matter study group (2005) (47)
- Bayesian MS Lesion Classification Modeling Regional and Local Spatial Information (2006) (47)
- Proton Magnetic Resonance Spectroscopic Imaging Can Predict Length of Survival in Patients with Supratentorial Gliomas (2003) (46)
- Improved correlation between scores on the expanded disability status scale and cerebral lesion load in relapsing-remitting multiple sclerosis. Results of the application of new imaging methods. (1998) (45)
- Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. (2003) (45)
- Proton MR spectroscopy in multiple sclerosis. (2000) (45)
- Elevated serum inflammatory markers in post-poliomyelitis syndrome (2008) (44)
- Surface‐based analysis reveals regions of reduced cortical magnetization transfer ratio in patients with multiple sclerosis: A proposed method for imaging subpial demyelination (2014) (44)
- Virus-induced autoimmune reactions in the CNS. (2001) (44)
- Application of calibrated fMRI in Alzheimer's disease (2017) (44)
- Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. (2010) (43)
- Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis (2014) (42)
- Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination (2016) (42)
- No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a (2018) (41)
- Quantitative magnetization transfer imaging made easy with qMTLab: Software for data simulation, analysis, and visualization (2015) (41)
- Imaging of repeated episodes of demyelination and remyelination in multiple sclerosis (2014) (41)
- Dual‐temporal resolution dynamic contrast‐enhanced MRI protocol for blood–brain barrier permeability measurement in enhancing multiple sclerosis lesions (2011) (40)
- Imaging outcome measures of neuroprotection and repair in MS (2019) (40)
- Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial (2020) (40)
- High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS (2019) (40)
- N‐acetylaspartate: Usefulness as an indicator of viable neuronal tissue (2001) (40)
- Interferon β-1b and glatiramer acetate effects on permanent black hole evolution (2011) (40)
- White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders (2017) (39)
- ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis (2017) (39)
- Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE (2020) (39)
- Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study (2014) (38)
- Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis (2016) (37)
- A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. (2004) (37)
- Fatigue in Post‐poliomyelitis Syndrome: Association With Disease‐Related, Behavioral, and Psychosocial Factors (2009) (37)
- Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial (2021) (37)
- Evidence for mitochondrial dysfunction in patients with alternating hemiplegia of childhood (1993) (37)
- Biological markers in the diagnosis and treatment of ALS (1999) (36)
- Prediction of Disease Progression in Multiple Sclerosis Patients using Deep Learning Analysis of MRI Data (2019) (36)
- MR spectroscopy and imaging in metabolic myopathies. (2000) (36)
- Metabolic Changes in Cerebral Gliomas Within Hours of Treatment With Intra-Arterial BCNU Demonstrated by Phosphorus Magnetic Resonance Spectroscopy (1987) (35)
- Monophasic demyelination reduces brain growth in children (2017) (35)
- MRI in the evaluation of pediatric multiple sclerosis (2016) (35)
- A surface‐in gradient of thalamic damage evolves in pediatric multiple sclerosis (2019) (35)
- Combining Robust Expectation Maximization and Mean Shift algorithms for Multiple Sclerosis Brain Segmentation (2008) (34)
- Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements (2019) (34)
- Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study (2019) (34)
- 1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient (1991) (33)
- Probabilistic Multiple Sclerosis Lesion Classification Based on Modeling Regional Intensity Variability and Local Neighborhood Information (2015) (33)
- Reproducibility of quantitative magnetization‐transfer imaging parameters from repeated measurements (2010) (32)
- Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study (2018) (32)
- Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials (2013) (31)
- Abnormal oxidative metabolism in exercise in exercise intolerance of undetermined origin (1997) (31)
- Intracellular phosphates in inclusion body myositis—A 31P magnetic resonance spectroscopy study (1998) (30)
- MS Lesion Segmentation using Markov Random Fields (2009) (29)
- The lesions of multiple sclerosis. (2002) (29)
- Memory Performance and Normalized Regional Brain Volumes in Patients with Pediatric-Onset Multiple Sclerosis (2012) (29)
- The role of MRS and fMRI in multiple sclerosis. (2006) (29)
- Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. (2000) (29)
- Magnetic Resonance Spectroscopy in Epilepsy: Clinical Issues (2002) (29)
- Imaging axonal damage in multiple sclerosis by means of MR spectroscopy (2000) (28)
- Secondary Progressive Multiple Sclerosis New Insights (2021) (28)
- Magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients (2014) (28)
- Improved Precision in the Measurement of Longitudinal Global and Regional Volumetric Changes via a Novel MRI Gradient Distortion Characterization and Correction Technique (2010) (28)
- Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis (2017) (28)
- Neuroprotection with glatiramer acetate: evidence from the PreCISe trial (2013) (28)
- Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis (2008) (28)
- Large, nonplateauing relationship between clinical disability and cerebral white matter lesion load in patients with multiple sclerosis. (2012) (28)
- Secondary Progressive Multiple Sclerosis (2021) (27)
- Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS (2008) (27)
- Early Metabolic Changes Following Chemotherapy of Human Gliomas In Vivo Demonstrated by Phosphorus Magnetic Resonance Spectroscopy (1989) (27)
- A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis (2017) (27)
- Lateralization of Temporal Lobe Epilepsy (TLE) and Discrimination of TLE from Extra‐TLE Using Pattern Analysis of Magnetic Resonance Spectroscopic and Volumetric Data (2000) (27)
- Relation of Interictal Spike Frequency to 1H‐MRSI‐Measured NAA/Cr (1999) (26)
- Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma (2008) (26)
- Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI (2019) (26)
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS (2016) (26)
- Temporal Hierarchical Adaptive Texture CRF for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI (2015) (25)
- Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis (2017) (25)
- Intracortical inhibition abnormality during the remission phase of multiple sclerosis is related to upper limb dexterity and lesions (2016) (24)
- Evidence for neuroprotection and remyelination using imaging techniques (2007) (24)
- Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial (2002) (24)
- The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk (2019) (24)
- Glutaric acidemia type II: neuroimaging and spectroscopy evidence for developmental encephalomyopathy. (1995) (23)
- Muscle phosphorus magnetic resonance spectroscopy oxidative indices correlate with physical activity (2000) (23)
- Statistics for Investigation of Multimodal MR Imaging Data and an Application to Multiple Sclerosis Patients (1996) (23)
- Proton MR spectroscopy to assess axonal damage in multiple sclerosis and other white matter disorders. (2000) (23)
- Non-Local Means Inpainting of MS Lesions in Longitudinal Image Processing (2015) (22)
- 1H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis (2009) (22)
- Neuroimaging in amyotrophic lateral sclerosis (2003) (22)
- Adaptive multi-level conditional random fields for detection and segmentation of small enhanced pathology in medical images (2016) (22)
- Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies (2016) (22)
- Heterogeneity of T‐lymphocyte function in primary progressive multiple sclerosis: Relation to magnetic resonance imaging lesion volume (2000) (22)
- Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study (2018) (21)
- Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial (2017) (21)
- Proton Magnetic Resonance Spectroscopic Imaging Studies in Patients with Newly Diagnosed Partial Epilepsy (2000) (21)
- Masquerades of Acquired Demyelination in Children (2013) (21)
- 1 H-MRS quantification of tNA and tCr in patients with multiple sclerosis : a meta-analytic review (2005) (21)
- Multiple Sclerosis Lesions Segmentation using Spectral Gradient and Graph Cuts (2008) (20)
- White matter plasticity and maturation in human cognition (2019) (20)
- Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation (2021) (20)
- Axonal Damage in Multiple Sclerosis Patients with High versus Low Expanded Disability Status Scale Score (2004) (20)
- Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial (2018) (19)
- Statistical Analysis of Longitudinal MRI Data: Applications for Detection of Disease Activity in MS (2002) (19)
- Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial (2021) (19)
- Magnetic Resonance Spectroscopy in Multiple Sclerosis (2001) (19)
- Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001) (2016) (18)
- Spectroscopic imaging of frontal neuronal dysfunction in hyperekplexia. (1998) (18)
- Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial (2021) (18)
- How patients with multiple sclerosis acquire disability (2022) (18)
- IMaGe: Iterative Multilevel Probabilistic Graphical Model for Detection and Segmentation of Multiple Sclerosis Lesions in Brain MRI (2015) (18)
- An Object-Based Method for Rician Noise Estimation in MR Images (2009) (18)
- Local Indicators of Spatial Autocorrelation (LISA): Application to Blind Noise-Based Perceptual Quality Metric Index for Magnetic Resonance Images (2019) (18)
- Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial (2022) (18)
- Altered resting-state functional connectivity in cognitively preserved pediatric-onset MS patients and relationship to structural damage and cognitive performance (2016) (18)
- Modeling in vivo recovery of intracellular pH in muscle to provide a novel index of proton handling: Application to the diagnosis of mitochondrial myopathy (2001) (17)
- Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results (2021) (17)
- Using Deep Learning Algorithms to Automatically Identify the Brain MRI Contrast: Implications for Managing Large Databases (2018) (17)
- Deep grey matter injury in multiple sclerosis: A NAIMS consensus statement. (2021) (17)
- Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways (2005) (16)
- MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis (2017) (16)
- Propagating Uncertainty Across Cascaded Medical Imaging Tasks for Improved Deep Learning Inference (2019) (16)
- Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease (2016) (16)
- Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions (2020) (16)
- Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring (2020) (15)
- Adaptive Voxel, Texture and Temporal Conditional Random Fields for Detection of Gad-Enhancing Multiple Sclerosis Lesions in Brain MRI (2013) (15)
- Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004) (2016) (15)
- MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b (2016) (15)
- Bayesian Classification of Multiple Sclerosis Lesions in Longitudinal MRI Using Subtraction Images (2010) (15)
- Neuronal dysfunction in children with newly diagnosed temporal lobe epilepsy. (2000) (14)
- Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001) (2013) (14)
- P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies (2017) (14)
- Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis (2020) (14)
- Intracellular phosphates in inclusion body myositis--a 31P magnetic resonance spectroscopy study. (1998) (14)
- Quantitative Measurement of tissue damage and recovery within new T2w lesions in pediatric- and adult-onset multiple sclerosis (2015) (14)
- Detection of Gad-Enhancing Lesions in Multiple Sclerosis Using Conditional Random Fields (2010) (14)
- Multivariate Statistics for Detection of MS Activity in Serial Multimodal MR Images (2003) (13)
- Incidence and prevalence of MS in children (2018) (13)
- Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN (2018) (13)
- Automated separation of diffusely abnormal white matter from focal white matter lesions on MRI in multiple sclerosis (2019) (12)
- BG-12 Increases the Proportion of Patients Free of Clinical and Radiologic Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (PD5.005) (2012) (12)
- CNN Detection of New and Enlarging Multiple Sclerosis Lesions from Longitudinal Mri Using Subtraction Images (2020) (12)
- The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes (2021) (12)
- Association of cerebral dysgenesis and lactic acidemia with X-linked PDH E1 alpha subunit mutations in females. (1995) (12)
- Predicting Future Disease Activity and Treatment Responders for Multiple Sclerosis Patients Using a Bag-of-Lesions Brain Representation (2017) (12)
- Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes (2021) (12)
- Magnetic resonance spectroscopy for monitoring neuronal integrity in amyotrophic lateral sclerosis. (2006) (12)
- Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies (2019) (12)
- Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM (2016) (12)
- Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. (2021) (12)
- Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy (2002) (11)
- Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. (2020) (11)
- Magnetization transfer ratio is unable to lateralize epileptic foci in patients with temporal lobe epilepsy. (2000) (11)
- Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? (2009) (11)
- No-reference quality measure in brain MRI images using binary operations, texture and set analysis (2017) (11)
- High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study (2019) (11)
- Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters (2018) (11)
- Normalization of White Matter Intensity on T1‐Weighted Images of Patients with Acquired Central Nervous System Demyelination (2015) (11)
- Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study (2020) (11)
- Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes (2021) (11)
- T2 Relaxometry Can Lateralize Mesial Temporal Lobe Epilepsy in Patients with Normal MRI Volume 11, Number 6, Part 2 (2000), pages 739–746 (2001) (10)
- Improving Pathological Structure Segmentation via Transfer Learning Across Diseases (2019) (10)
- Optimal Gaussian Mixture Models of Tissue Intensities in Brain MRI of Patients with Multiple-Sclerosis (2010) (10)
- Clinical Efficacy of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P07.097) (2013) (10)
- Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations (2015) (10)
- Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial (2016) (10)
- Brain phosphorus magnetic resonance spectroscopy in acute bacterial meningitis. (1989) (9)
- Delineation of cortical pathology in multiple sclerosis using multi-surface magnetization transfer ratio imaging (2016) (9)
- Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis (2016) (9)
- MRI and Proton MRS in the Evaluation of Multiple Sclerosis (1997) (9)
- Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don’t (2014) (9)
- Phosphorus magnetic resonance spectroscopy of brain in mitochondrial cytopathies (1990) (9)
- Durable Effect of Alemtuzumab on MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS II (P7.249) (2015) (9)
- Axonal Injury and Disability in Multiple Sclerosis: Magnetic Resonance Spectroscopy as a Measure of Dynamic Pathological Change in White Matter (2001) (9)
- Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy (2013) (9)
- Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis (2016) (9)
- Lesion Detection, Segmentation and Prediction in Multiple Sclerosis Clinical Trials (2017) (9)
- Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI (2018) (9)
- Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials (2021) (9)
- Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years (2022) (9)
- Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes (2016) (8)
- A Generative Model for Automatic Detection of Resolving Multiple Sclerosis Lesions (2014) (8)
- The relation of focal white matter signal abnormality and focal volume loss in multiple sclerosis (2007) (8)
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis (2020) (8)
- Efficacy of Ocrelizumab in Patients with Relapsing Multiple Sclerosis: Pooled Analysis of Two Identical Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled Studies (S49.003) (2016) (8)
- Durable Effect of Alemtuzumab on MRI Activity in Treatment-Naive Active Relapsing-Remitting Multiple Sclerosis Patients: 4-Year Follow-up of CARE-MS I (P7.246) (2015) (8)
- Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much? (2009) (8)
- Efficacy and Safety of Alemtuzumab in Treatment-Naive Patients with Relapsing-Remitting MS: Four-Year Follow-up of the CARE-MS I Study (2015) (8)
- Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) (P3.396) (2018) (8)
- Patients with Active RRMS and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study (P3.022) (2016) (8)
- Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis (2018) (8)
- Hierarchical Conditional Random Fields for Detection of Gad-Enhancing Lesions in Multiple Sclerosis (2012) (8)
- Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial (2022) (8)
- Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (S01.004) (2012) (8)
- Bayesian framework inspired no-reference region-of-interest quality measure for brain MRI images (2017) (7)
- Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve Patients (S01.006) (2012) (7)
- The clique potential of Markov random field in a random experiment for estimation of noise levels in 2D brain MRI (2013) (7)
- Chapter 10 Magnetic Resonance Imaging and Spectroscopy: Insights into the Pathology and Pathophysiology of Multiple Sclerosis (2003) (7)
- Efficacy Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Adults with Relapsing Multiple Sclerosis (P7.198) (2015) (7)
- Optimal selection of regularization parameter in total variation method for reducing noise in magnetic resonance images of the brain (2014) (7)
- Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis (2015) (7)
- Incidence of Infection Decreases Over Time in Alemtuzumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 4-Year Follow-up of the CARE-MS Studies (P7.265) (2015) (7)
- Imaging of Demyelination and Remyelination in Multiple Sclerosis (2013) (7)
- Pooled Analyses from the ALLEGRO and BRAVO Trials on the Safety and Tolerability of Laquinimod as a Multiple Sclerosis Treatment (P04.132) (2012) (7)
- Brain volume loss in individuals over time: Source of variance and limits of detectability (2020) (7)
- Incidence and Timing of Thyroid Adverse Events in Patients with RRMS Treated with Alemtuzumab through 5 Years of the CARE-MS Studies (P2.086) (2016) (7)
- Improving the SIENA performance using BEaST brain extraction (2018) (7)
- Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007) (2012) (7)
- Muscle high-energy phosphates in central nervous system disorders. The phosphorus MRS experience (1997) (7)
- Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (2018) (7)
- Erratum to: Optimal selection of regularization parameter in total variation method for reducing noise in magnetic resonance images of the brain (2014) (6)
- Safety and Tolerability Results From the DECIDE Study: A Phase 3 Active-Comparator Study of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis (P7.230) (2015) (6)
- white matter lesion load in patients with secondary progressive multiple sclerosis (2009) (6)
- Chronic lesion activity and disability progression in secondary progressive multiple sclerosis (2022) (6)
- Alemtuzumab Slows Brain Volume Loss Over 4 Years Despite Most Relapsing-Remitting Multiple Sclerosis Patients Not Receiving Treatment for 3 Years (P7.263) (2015) (6)
- Use of Imaging in Multiple Sclerosis (2010) (6)
- Brain volume and fatigue in patients with postpoliomyelitis syndrome. (2014) (6)
- Proton magnetic resonance spectroscopy in brain white matter disorders (1997) (6)
- Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study) (2013) (6)
- Increased mental health care use by mothers of children with multiple sclerosis (2020) (6)
- Corrigendum to “Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change” [NeuroImage 49 (2010) 1601–1611] (2010) (6)
- Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003) (2015) (6)
- Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study (2022) (6)
- No Evidence for Impairment of Venous Hemodynamics in Children or Young Adults with Pediatric-Onset Multiple Sclerosis (2013) (6)
- Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101) (2013) (6)
- The Metabolic Epicenter of Supratentorial Gliomas: A 1H-MRSI Study (2009) (6)
- Evaluation of no evidence of progression using composite outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial (2016) (6)
- Path Sampling to Compute Integrated Likelihoods: An Adaptive Approach (2009) (6)
- Proton Magnetic Resonance Spectroscopy (2002) (6)
- Effect of Alemtuzumab vs. Rebif(R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study (S11.006) (2012) (6)
- N-acetylaspartate: A marker of neuronal integrity. Authors' reply (2001) (5)
- Effect of BG-12 on Brain Atrophy and Lesions Volume: MRI Results from the DEFINE Study during First and Second Year of Treatment (IN3-2.002) (2012) (5)
- Image Quality Evaluation in Clinical Research: A Case Study on Brain and Cardiac MRI Images in Multi-Center Clinical Trials (2018) (5)
- Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017) (2015) (5)
- MRI inter-packet movement correction for images acquired with non-complementary data (2008) (5)
- Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001) (2016) (5)
- ADVANCE Phase 3 Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis: Patient Baseline Characteristics (P01.133) (2012) (5)
- Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174) (2013) (5)
- Clinical Efficacy and Safety of Peginterferon beta-1a in Relapsing Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S31.006) (2013) (5)
- Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. (2019) (5)
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study (2020) (5)
- Durable Effect of Alemtuzumab on Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients: Four-Year Follow-up of CARE-MS I (S4.007) (2015) (5)
- Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201) (2015) (5)
- ASCEND Phase 3 Trial Open-Label Extension Study Results: Natalizumab May Delay Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (P5.330) (2017) (5)
- Diagnostic Tests in Neurology (1991) (5)
- Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study (2013) (5)
- CNN Prediction of Future Disease Activity for Multiple Sclerosis Patients from Baseline MRI and Lesion Labels (2018) (5)
- The place of MRI in monitoring the individual MS patient (2007) (5)
- Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise (2021) (4)
- Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) (2019) (4)
- Counterfactual Image Synthesis for Discovery of Personalized Predictive Image Markers (2022) (4)
- Brain MRI Intensity Inhomogeneity Correction Using Region of Interest, Anatomic Structural Map, and Outlier Detection (2016) (4)
- Serum Neurofilament Light (NfL): Towards a Blood Test for Prognosis and Disease/Treatment Monitoring in Multiple Sclerosis Patients (S24.003) (2018) (4)
- A new metabolic myopathy: a malate-aspartate-shuttle defect (1986) (4)
- CLINICAL AND NEURORADIOLOGICAL EFFECT OF BG-12 (DIMETHYL FUMARATE) IN SUBGROUPS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF THE PHASE 3 DEFINE AND CONFIRM STUDIES (2013) (4)
- Trial Designs Likely to Meet Valid Long-Term Alzheimer's Disease Progression Effects: Learning from the Past, Preparing for the Future (2009) (4)
- Normalization of Magnetization Transfer Ratio MRI For Multicentre Clinical Trials (2010) (4)
- The Efficacy of Alemtuzumab Is Maintained in Patients Who Develop Thyroid Adverse Events (P7.272) (2015) (4)
- Surface-based techniques reveal regions of reduced cortical magnetization transfer ratio in patients with MS (2009) (4)
- Ocrelizumab May Reduce Tissue Damage in Chronic Active Lesions as Measured by Change in T1 Hypo-Intensity of Slowly Evolving Lesions in Patients With Primary Progressive Multiple Sclerosis (P3.376) (2018) (4)
- Magnetic resonance spectroscopy of multiple sclerosis: imaging axonal damage (2001) (4)
- Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria (2022) (4)
- Time Course of Postoperative Recovery of N‐Acetyl‐Aspartate in Temporal Lobe Epilepsy (2001) (4)
- Metabolic and functional imaging of brain tumors (2001) (4)
- Effects of BG-12 on Magnetization Transfer Ratio in Whole Brain and Normal-Appearing Brain Tissue: Findings from the DEFINE Study (S11.004) (2012) (4)
- Regions of reduced cortical magnetization transfer ratio detected in MS patients using surface-based techniques (2009) (4)
- Slowly expanding lesions are a marker of progressive MS – No (2021) (4)
- Evidence for use of glatiramer acetate in multiple sclerosis (2005) (4)
- Axonal pathology in patients with multiple sclerosis: evidence from in vivo proton magnetic resonance spectroscopy (2007) (4)
- Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: 2-Year Follow-up Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI) (2013) (4)
- Factors associated with health care utilization in pediatric multiple sclerosis. (2019) (4)
- Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.006) (2018) (4)
- Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093) (2013) (4)
- Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation. (2021) (3)
- RRMS Patients Switching from SC IFNB-1a to Alemtuzumab in the CARE-MS I and II Extension Study Have a Reduced Rate of Brain Volume Loss (P6.183) (2016) (3)
- Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002) (2016) (3)
- Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination (2021) (3)
- Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis (2018) (3)
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase 1 trial (Annals of Neurology (2007) (399-495)) (2008) (3)
- Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome (2021) (3)
- Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.098) (2013) (3)
- Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis (2021) (3)
- MT-1303, a novel selective s1p1 receptor modulator in RRMS - results of a placebo controlled, double blind phase II trial (momentum) (2015) (3)
- Seeing injectable MS therapies differently (2009) (3)
- Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis I (CARE-MS I) (S41.006) (2012) (3)
- Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study (2018) (3)
- Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials (2022) (3)
- Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (S6.002) (2018) (3)
- The spatial statistics of structural magnetic resonance images: application to post-acquisition quality assessment of brain MRI images (2017) (3)
- Uncertainty for Safe Utilization of Machine Learning in Medical Imaging and Clinical Image-Based Procedures: First International Workshop, UNSURE 2019, and 8th International Workshop, CLIP 2019, Held in Conjunction with MICCAI 2019, Shenzhen, China, October 17, 2019, Proceedings (2019) (3)
- Effect of Ocrelizumab on Disability Progression in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.008) (2016) (3)
- Is It Possible to Differentiate the Impact of Pediatric Monophasic Demyelinating Disorders and Multiple Sclerosis After a First Episode of Demyelination? (2014) (3)
- MRI Visualization of Multiple Sclerosis (2004) (3)
- Influence of the training library composition on a patch-based label fusion method: Application to hippocampus segmentation on the ADNI dataset (2011) (3)
- Safety and Tolerability Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Relapsing Multiple Sclerosis (P7.199) (2015) (3)
- Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study (2022) (3)
- The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. (2022) (3)
- Rate of Brain Volume Loss with Long-Term Delayed-Release Dimethyl Fumarate Treatment in Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Results from ENDORSE (P3.061) (2016) (3)
- 061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE) (2018) (3)
- Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses (2009) (3)
- Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon β-1a in Relapsing Multiple Sclerosis (RMS) (P3.410) (2018) (3)
- Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes (2018) (3)
- Redefining multiple sclerosis phenotypes using MRI (2019) (3)
- Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130) (2020) (3)
- P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies (2017) (2)
- Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS (2022) (2)
- Treatment-Naive Patients with Active RRMS Who Received Alemtuzumab Demonstrate Durable Suppression of New MRI Lesion Formation: 5-Year Follow-Up of the CARE-MS I Study (S51.002) (2016) (2)
- Defining multiple sclerosis subtypes using machine learning (2019) (2)
- Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II): Subgroup Analysis by Previous Disease Modifying Therapy (DMT) Use (P07.111) (2013) (2)
- COENZYME Q. AUTHORS' REPLY (1993) (2)
- Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P01.130) (2012) (2)
- Object-based Rician Noise Estimation for MR Images (2009) (2)
- PO129 Neda analysis by epoch in the opera studies of ocrelizumab (2017) (2)
- PND63 Effects of BG-12 on Quality of Life in Relapsing–Remitting Multiple Sclerosis: Findings From the Phase 3 Define Study (2012) (2)
- Optimizing Operating Points for High Performance Lesion Detection and Segmentation Using Lesion Size Reweighting (2021) (2)
- Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective (2022) (2)
- Regional Brain Atrophy in Multiple Sclerosis : increasing sensitivity to differences in relapsing-remitting and secondary-progressive disease (2001) (2)
- Relapse Outcomes with Alemtuzumab vs. Rebif® in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints (PD5.004) (2012) (2)
- Interim Analysis of 2-year Clinical Efficacy and Safety of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S4.005) (2014) (2)
- Assessing the differential sensitivities of wave-CAIPI ViSTa myelin water fraction and magnetization transfer saturation for efficiently quantifying tissue damage in MS. (2021) (2)
- Improvement in Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients Who Switched From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7.270) (2015) (2)
- Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy (2014) (2)
- Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I Study (S51.004) (2016) (2)
- 148Immunoablative therapy with purified autologous stem cells rescue for the treatment of poor prognosis MS (2003) (2)
- Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study (2017) (2)
- Neuroradiological efficacy of oral BG-12 for relapsing–/INS;remitting multiple sclerosis (RRMS): Integrated analysis of the Phase 3 DEFINE and CONFIRM studies (2013) (2)
- Daclizumab HYP Reduced Brain MRI Lesion Activity Compared With Interferon Beta-1a: Results from the DECIDE Study (P7.252) (2015) (2)
- Durable Efficacy in RRMS Patients Receiving Two Annual Courses of Alemtuzumab and No Additional Treatment for 4 Years: Pooled Analysis of CARE-MS I and II (S51.005) (2016) (2)
- Long-Term Efficacy in MRI and No Evidence of Disease Activity Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Peginterferon Beta-1a (P7.266) (2015) (2)
- Exploratory MRI Biomarkers of Opicinumab (Anti-LINGO-1) Show Stabilization of Pre-existing T2 Lesions in Relapsing Multiple Sclerosis: Results from the Phase 2b SYNERGY Trial (P2.100) (2017) (2)
- Saliency Based Deep Neural Network for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI (2019) (2)
- Natalizumab-Treated Patients with Multiple Sclerosis Have Low Rates of Brain Volume Decrease and Low MRI Disease Activity in the Long-term STRATA Study (P7.260) (2015) (2)
- STRATEGIES FOR MONITORING AND ASSESSING THERAPY (2006) (2)
- Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis (2016) (2)
- Slowing of Brain Volume Loss in Patients With Relapsing-Remitting Multiple Sclerosis After Switching From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7.264) (2015) (2)
- Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis: MRI Outcomes from DEFINE, CONFIRM, and ENDORSE (P7.262) (2015) (2)
- Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials (2018) (2)
- Predictors of an Opicinumab Treatment Effect and Identification of an Efficacy Subpopulation: A Post hoc Analysis of the SYNERGY Study (P3.408) (2018) (2)
- Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: Early Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI) (2011) (2)
- Phase 2 AFFINITY trial evaluates opicinumab in a targeted population of patients with relapsing multiple sclerosis: rationale, design and baseline characteristics (2018) (2)
- Switching to Alemtuzumab From Subcutaneous Interferon Beta-1a After CARE-MS II Further Improved MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis (P7.248) (2015) (2)
- Five-year outcomes of halt-MS: high-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe relapsing-remitting multiple sclerosis (2016) (2)
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis (2020) (2)
- Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I) (S41.007) (2012) (2)
- Long-Term Responders from the CARE-MS I Study: No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment (P3.054) (2016) (2)
- Author Correction: Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data (2021) (2)
- A power analysis for multisite studies in resting-state functional connectivity, with an application to clinical trials in Alzheimer's disease (2013) (2)
- Statistical power and measurement bias in multisite resting-state fMRI connectivity (2016) (2)
- 056 Efficacy and safety of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study (2019) (1)
- Robust automatic segmentation and characterization of lateral ventricle size in the ADNI cohort (2010) (1)
- Effects of temporal resolution on blood-brain barrier permeability measurement with Dynamic Contrast Enhanced MRI in multiple sclerosis enhancing lesions (2010) (1)
- The search for the missing links in multiple sclerosis (2007) (1)
- Cohort Bias Adaptation in Aggregated Datasets for Lesion Segmentation (2021) (1)
- Prospective characterization of children positive for anti-MOG antibodies meeting Multiple Sclerosis diagnostic criteria (2019) (1)
- ESTIMATING AND ACCOUNTING FOR THE EFFECT OF MRI SCANNER HARDWARE CHANGES ON LONGITUDINAL WHOLE-BRAIN ATROPHY MEASUREMENTS (2016) (1)
- Sustained low rate of brain volume loss with long-term delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis patients: results from the ENDORSE study (2015) (1)
- beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis (2002) (1)
- Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) (2019) (1)
- Impact Of Obstructive Sleep Apnea-Hypopnea Treatment On Fatigue In Multiple Sclerosis (2010) (1)
- Disease Management in Multiple Sclerosis (2005) (1)
- Measuring injury and repair of myelin and neurons in multiple sclerosis. (2005) (1)
- Combined MRI Measure of Active Lesions and Brain Atrophy as a Surrogate for Disability in Multiple Sclerosis: A Meta-Analysis of Randomized Trials (P07.096) (2013) (1)
- Baseline Characteristics of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon-β-1a (P1.347) (2017) (1)
- Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial (2023) (1)
- 086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study (2018) (1)
- Multiple sclerosis (PP-038) (2010) (1)
- Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P07.102) (2012) (1)
- Magnetization Transfer Ratio Imaging Is Feasible in Large Multicenter MS Trials (2010) (1)
- Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study (S12.006) (2017) (1)
- Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis (2022) (1)
- MUSCLE ACIDOSIS IN POST-VIRAL FATIGUE (1984) (1)
- Rate of Agreement for Manual and Automated Techniques for Determination of New T2 Lesions in Children with Multiple Sclerosis and Acute Demyelination (P2.242) (2014) (1)
- Six-year follow-up of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM and ENDORSE (2015) (1)
- Proton MR Spectroscopic Imaging in The Investigation of Patients with Temporal Lobe Epilepsy (1994) (1)
- Alemtuzumab-Treated Patients Experienced Decreased MRI Disease Activity and Slowing of Brain Volume Loss Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS I (TOPAZ Study) (S36.003) (2018) (1)
- Segmentation-Consistent Probabilistic Lesion Counting (2022) (1)
- Axonal Integrity and Fractional Anisotropy in the Normal-Appearing White Matter of Patients with Multiple Sclerosis : Relationship to Cerebro-Functional Reorganization and Clinical Disability (1999) (1)
- Improvement in Clinical Outcomes Following Switch From Subcutaneous Interferon Beta-1a to Alemtuzumab: CARE-MS II Extension Study (P7.278) (2015) (1)
- Patients with Active RRMS and an Inadequate Response to Prior Therapy Who Received Alemtuzumab Demonstrate Durable Suppression of New MRI Lesion Formation: 5-Year Follow-Up of the CARE-MS II Study (P3.112) (2016) (1)
- Cortical Surface Analysis of Multi-contrast MR Data to Improve Detection of Cortical Pathology in Multiple Sclerosis (2013) (1)
- Alemtuzumab Reduced MRI Lesions and the Rate of Brain Volume Loss in CARE-MS II Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (P5.031) (2018) (1)
- Four‐neighborhood clique kernel: A general framework for Bayesian and variational techniques of noise reduction in magnetic resonance images of the brain (2014) (1)
- Five-year follow-up of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM, and ENDORSE (2014) (1)
- Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (2013) (1)
- Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005) (2018) (1)
- The Relevance of Normal-Appearing White Matter Pathology in Multiple Sclerosis (2004) (1)
- Differential Diagnosis of Human Intracranial Tumors in Vivo Using 1H Mr Spectroscopic Imaging and Feature Space for Spectral Pattern Recognition (1994) (1)
- Automated Detection of Focal Cortical Dysplasia based on Textural, Statistical and Morphological Analysis of MRI (2003) (1)
- ESTIMATING AND ACCOUNTING FOR THE EFFECT OF MRI SCANNER HARDWARE CHANGES ON LONGITUDINAL WHOLE-BRAIN ATROPHY MEASUREMENTS (2016) (1)
- Patients Who Switched from SC IFNB-1a to Alemtuzumab in the CARE-MS II Extension Study Show Durable Improvements in Clinical Outcomes (P3.024) (2016) (1)
- Results from the 48-Week Blinded Extension of RADIANCE: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis (P3.023) (2016) (1)
- Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study (2017) (1)
- No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-Term Responders from the CARE-MS II Study (P3.059) (2016) (1)
- Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. (2021) (1)
- Effects of oral ELND005 (Scyllo-inositol) on brain scyllo-inositol and myo-inositol levels: Spectroscopy results from a phase 2 study in MILD-TO-MODERATE Alzheimer's disease (2012) (1)
- Robust automatic segmentation of hippocampus from multisite MRI data (2009) (1)
- Predicting disability progression and cognitive worsening in multiple sclerosis using grey matter network measures (2021) (1)
- Sleep-Disordered Breathing (SDB) and Fatigue in Multiple Sclerosis (MS). (2009) (1)
- Sustained Low Rate of Brain Volume Loss under Long-term Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis Patients: Results from the ENDORSE Study (P7.243) (2015) (1)
- Primary Analysis of a Randomized Phase II Study to Evaluate the Efficacy and Safety of Evobrutinib, a BTK Inhibitor, in Patients with Relapsing MS (2019) (1)
- Three-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated magnetic resonance imaging (MRI) outcomes from DEFINE, CONFIRM, and ENDORSE (2013) (1)
- Multiple Sclerosis Therapeutics: Axonal pathology in patients with multiple sclerosis (2011) (1)
- Proton Magnetic Resonance Spectroscopic Imaging and Magnetic Resonance Imaging Volumetry in the Lateralization of Temporal Lobe Epilepsy : A Series of 100 Patiekts (2004) (1)
- Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning (2022) (1)
- MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial (2023) (1)
- P.107 Personalized prediction of future lesion activity and treatment effect in multiple sclerosis from baseline MRI (2022) (1)
- Adapted MRF Segmentation of Multiple Sclerosis Lesions Using Local Contextual Information (2011) (1)
- Contents Vol. 53, 2005 (2005) (1)
- Effect of Interferon beta-1b and Glatiramer Acetate on New MTR Brain Lesions in MS (P07.104) (2013) (1)
- Results of the 48-Week Blinded Extension of RADIANCE: a Randomized, Placebo-controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis (2016) (0)
- Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis (2022) (0)
- Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study (2021) (0)
- Durable Reduction in MRI Disease Activity and Slowing of Brain Volume Loss in Alemtuzumab-Treated Patients With Active RRMS: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) (P6.375) (2018) (0)
- 060 Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE) (2018) (0)
- The Axonal Hypothesis and Magnetic Resonance Spectroscopy of MS (1998) (0)
- Alemtuzumab Decreased MRI Disease Activity Over 4 Years in Patients Who Switched From SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up (S12.007) (2017) (0)
- Prospective clinical and MRI characterization of children with serum anti-MOG antibodies meeting the multiple sclerosis diagnostic criteria (2018) (0)
- Peginterferon Beta-1a Reduces Conversion of MRI Lesions to Black Holes in Patients with Relapsing-Remitting Multiple Sclerosis (P3.091) (2016) (0)
- MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results (P6-3.012) (2023) (0)
- Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010) (2023) (0)
- Peginterferon Beta-1a Demonstrated Sustained Efficacy in Newly Diagnosed Relapsing Multiple Sclerosis (RMS) Patients Treated up to 4 Years: Subgroup Analysis of ATTAIN (P6.386) (2018) (0)
- Estimating treatment effect for individuals with progressive multiple sclerosis using deep learning (2021) (0)
- MD1003 in Progressive Multiple Sclerosis: 24-Month Brain Volume Changes of the MS-SPI Trial (P6.365) (2018) (0)
- Radiomics-based Unsupervised Clustering of Acute Multiple Sclerosis Lesions (P10-3.015) (2023) (0)
- Relapsing-Remitting Multiple Sclerosis Effectively Treated with Peginterferon Beta-1 (2014) (0)
- O4-06-02 EFFECTS OF HUMAN INTRAVENOUS IMMUNOGLOBULINS ON AMYLOID PATHOLOGY AND INFLAMMATION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE (2011) (0)
- 3-Year Follow-up of Oral BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated MRI Outcomes from the DEFINE, CONFIRM, and ENDORSE studies (2014) (0)
- Magnetic Resonance Spectroscopy in Niemann-Pick Type C: Corrdation With Di is Clinical Response to Ch styramine and Lovas tin (1994) (0)
- Mutations in Females Introduction Pyruvate dehydrogenase (PDH) deficiency is a major (1995) (0)
- Letters to the editor (1978) (0)
- Fully-automated MRI quantification of lateral-ventricle volume and volume-change in patients with Alzheimer ’ s disease (2009) (0)
- Thanks to Reviewers (2002) (0)
- Corrigendum to “Intracortical inhibition abnormality during the remission phase of multiple sclerosis is related to upper limb dexterity and lesions” [Clin. Neurophysiol. 127 (2016) 1503–1511] (2017) (0)
- GREATER PERIPHERAL THAN CENTRAL ADAPTATION TO AEROBIC TRAINING IN MITOCHONDRIAL MYOPATHIES 186 (1997) (0)
- Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies (2022) (0)
- Deep Learning Reconstruction of Lesion-Free Representations of the Brain in Multiple Sclerosis Patients (P11-3.006) (2023) (0)
- In Relapsing Multiple Sclerosis, Peginterferon Beta-1a Reduces MRI Lesions Following Relapses (P7.256) (2015) (0)
- Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up (2020) (0)
- Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis (2019) (0)
- Imaging and cerebrospinal fluid biomarker results of a phase II dose-ranging study of ELND005 (Scyllo-inositol) in mild-to-moderate Alzheimer's disease (2011) (0)
- Prediction of Progression in Multiple Sclerosis Patients (2018) (0)
- The effect of head positioning and repositioning on SIENA-generated measures of brain volume change: Results from simulated Z-shifts (2009) (0)
- Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions (2022) (0)
- Measuring Brain Volume in Patients with Multiple Sclerosis: A Comparison of Three Common Approaches (2009) (0)
- Proteogenomic immune signatures delineate the landscape of pediatric acquired demyelinating syndromes (2022) (0)
- PR_144: The Association of Fatigue With Brain Metabolites in Postpoliomyelitis Syndrome (2006) (0)
- Subject Index Vol. 53, 2005 (2005) (0)
- The Spatial Statistics of Structural Magnetic Resonance Images: Application to Quality Assessment of Brain MRI Images (2016) (0)
- Chapter 54 MRS for imaging neuronal dysfunction in epilepsy (2002) (0)
- Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis (2015) (0)
- An integrated analysis of the clinical and neuroradiological effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies (2013) (0)
- Diroximel Fumarate (DRF) in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Efficacy and Safety Results From the Phase 3 EVOLVE-MS-1 Study (P3.2-060) (2019) (0)
- Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study) (2019) (0)
- MRI evidence that gadolinium-enhancing lesions seen twelve weeks after commencing rituximab treatment are associated with lower blood-brain-barrier disruption than those seen prior to treatment in patients with relapsing-remitting multiple sclerosis (2008) (0)
- Peginterferon Beta-1a Significantly Increases the Proportion of Patients with Freedom from Measured Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the ADVANCE Study (S4.007) (2014) (0)
- Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. (2023) (0)
- Data from: Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice (2019) (0)
- Functional Magnetic Resonance Imaging and Multiple Sclerosis: Cortical Reorganisation and Recovery (2001) (0)
- The effect of head positioning and repositioning on SIENA-generated measures of brain volume change: Results from actual Z-shifts (2009) (0)
- MOG-IgG1 antibodies in children. (2018) (0)
- Myelin Water Fraction of Slowly Evolving Lesions is Associated With Disability in Multiple Sclerosis (P10-3.017) (2023) (0)
- Heatmap Regression for Lesion Detection using Pointwise Annotations (2022) (0)
- Clinically Plausible Pathology-Anatomy Disentanglement in Patient Brain MRI with Structured Variational Priors (2022) (0)
- Precision of longitudinal measures of cortical grey matter thickness change and ventricular volume change: comparison to the difference of cross-sectional measures, using multicenter scan-reposition-rescan MRI data (2010) (0)
- Magnetic resonance spectroscopy in epilepsy (2002) (0)
- Subgroup and Sensitivity Analyses of the Primary Endpoint from the Peginterferon Beta-1a ADVANCE Study: A Pivotal Phase 3 Study in Patients with Relapsing-Remitting Multiple Sclerosis (P3.169) (2014) (0)
- Robust automatic segmentation and characterization of lateral ventricle size in the ADNI cohort (2010) (0)
- IC-P-013 Greater frontal than cingulate magnetic resonance spectroscopy abnormalities in early Alzheimer disease (2006) (0)
- Early Clinical and MRI Predictors of Time to Second Attack and Disability in Children with Acute Demyelinating Syndromes: Findings from a Prospective National Cohort Study (S54.007) (2014) (0)
- Abnormal responses of CD8+CD161high mucosal associated invariant T (MAIT) cells and CCR2+CCR5+ CD4 T cells contribute to disrupted balance of effector and regulatory T cells in pediatric-onset MS (2014) (0)
- Differential Regional Brain Atrophy Following Prophylactic Cranial Irradiation in Small Cell Lung Cancer Patients (2008) (0)
- PO127 Composite confirmed disability progression in oratorio (2017) (0)
- Patients Who Discontinued SC IFNB-1a and Switched to Alemtuzumab in the CARE-MS II Extension Study Show Durable Reduction in New Lesion Activity (P3.025) (2016) (0)
- Combining SIENA and SIENAx for improved quantification of grey and white matter atrophy (2011) (0)
- Sleep-disordered Breathing Is Associated With Pain In Multiple Sclerosis (2010) (0)
- MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-term Safety (LTS) Study (P6-3.017) (2023) (0)
- Imaging biomarkers in multiple sclerosis (2010) (0)
- Using Deep Learning Algorithms to Automatically Identify the Brain MRI Contrast: Implications for Managing Large Databases (2018) (0)
- Coenzyme Q (1993) (0)
- Acknowledgment: List of Reviewers (2006) (0)
- Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters (2018) (0)
- Rethinking Generalization: The Impact of Annotation Style on Medical Image Segmentation (2022) (0)
- Active RRMS Patients Treated with Alemtuzumab Experience Durable Reductions in MRI Disease Activity and Slowing of Brain Volume Loss: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.367) (2018) (0)
- 4-Year Follow-up of Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Magnetic Resonance Imaging (MRI) Outcomes From DEFINE, CONFIRM, and the ENDORSE Extension Study (P3.160) (2014) (0)
- Retinal Nerve Fiber Layer (RNFL) and Ganglion Cell Inner Plexiform Layer (GCIPL) in Persistently Myelin Oligodendrocyte Glycoprotein Antibody Positive Youth (P3.330) (2018) (0)
- Predicting personalised risk of disability worsening in multiple sclerosis with machine learning (2022) (0)
- Effects of Fingolimod on MRI Outcomes in Patients with Pediatric Onset Multiple Sclerosis: Results from Phase 3 PARADIGMS Study (S51.005) (2018) (0)
- Clinical Research Relation of Interictal Spike Frequency to H-MRSI-Measured NAA/Cr (1999) (0)
- Development Of Silent Brain Lesions In Pediatric Patients With Antibodies To Myelin Oligodendrocyte Glycoprotein (2020) (0)
- Treatment with Alemtuzumab Leads to Durable Benefits in Patients with Multiple Sclerosis (2014) (0)
- Serum 25‐hydroxyvitamin D as a determinant of multiple sclerosis outcome following a pediatric demyelinating event (2009) (0)
- Reply: To PMID 24006277. (2014) (0)
- 069 Peginterferon beta-1a improves clinical and radiological disease outcomes in patients who are newly diagnosed with relapsing-remitting multiple sclerosis (RRMS): subgroup analysis of advance (2018) (0)
- Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS (P6-3.013) (2023) (0)
- 200 AFFINITY: opicinumab in a targeted population of MS patients (2019) (0)
- A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS (2016) (0)
- Patterns of white and gray structural abnormality associated with paediatric demyelinating disorders (2022) (0)
- 2010 McDonald Criteria for Diagnosing Pediatric Multiple Sclerosis (P01.155) (2012) (0)
- Astrocytic Brain Tumors and Isolated Demyelinating Lesions of the Type Seen in Multiple Sclerosis Using H Magnetic Resonance Spectroscopic Imaging 1 (2004) (0)
- P2-324 Greater frontal than cingulate magnetic resonance spectroscopy abnormalities in early Alzheimer’s disease (2006) (0)
- Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. (2023) (0)
- P1-225: Effects of actual and simulated Z-shifts on freesurfer-segmented whole-brain-tissue, hippocampal, and lateral-ventricle volumes (2008) (0)
- Localization and Registration Issues Important for Serial MRS Studies of Focal Brain Lesions (2007) (0)
- Reply (2014) (0)
- The effect of head positioning and repositioning on SIENA-generated measures of brain volume change: Results from actual Z-shifts (2009) (0)
- Phenotypic and Functional Analysis of Immune Cell Subsets in Pediatric-onset Multiple Sclerosis (MS): Towards Definition of Earliest Disease Mechanisms (P2.236) (2014) (0)
- Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120) (2013) (0)
- The effect of head positioning and repositioning on SIENA-generated measures of brain volume change: Results from simulated Z-shifts (2009) (0)
- INDICES CORRELATE WITH PHYSICAL ACTIVITY (0)
- ADVANCE Trial: PEG-IFN- -1a Every 2 Weeks Significantly Improved Outcomes over 2 Years in RRMS (2014) (0)
- 136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS (2022) (0)
- Diffusion Tensor Imaging: Abnormal White Matter at the Time of a First Attack Distinguishes Children with Multiple Sclerosis from Children with Monophasic Demyelination and from Healthy Children (S50.007) (2012) (0)
- 2-13-02 Correlation between brain axonal damage and central nervous system impairment in brain white matter disorders (1997) (0)
- Influence of the training library composition on a patch-based label fusion method: Application to hippocampus segmentation on the ADNI dataset (2011) (0)
- A RARE PRESENTATION OF A RARE DISEASE: ADULT ONSET KRABBE ’ S DISEASE PRESENTING WITH PROGRESSIVE HYPERTROPHIC POLYRADICULONEUROPATHY TAKOTSUBO CARDIOMYOPATHY AND MYASTHENIC CRISES: A CASE SERIES IMPAIRED COLOR DISCRIMINATION IS ASSOCIATED WITH HALLUCINATIONS IN DEMENTIA WITH LEWY BODIES (2020) (0)
- Lateral ventricle segmentation based on fusion of expert priors in AD . (2009) (0)
- Effectiveness of Intensity Normalization on Human Brain MRIs with Multiple Sclerosis (2009) (0)
- Evidence Of Impaired Age-Expected Growth And Atrophy Of The Cerebellum In Pediatric Patients With Monophasic Acquired Demyelinating Syndrome And Multiple Sclerosis (S60.001) (2014) (0)
- Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN. (2021) (0)
- Adaptive local reorganisation of primary motor cortex after brain injury (2000) (0)
- Simulation-based power analysis could improve the design of clinical trials in Alzheimer's disease (2022) (0)
- Lack of Rebound Disease Activity in Participants with Relapsing Multiple Sclerosis Following Placebo Run-out in the Tolebrutinib Phase 2b Trial (P6-3.006) (2023) (0)
- MRI Features Distinguish Monophasic ADEM from MS: Findings from a Canadian Cohort of Children with Incident CNS Demyelination (S50.002) (2012) (0)
- DECIDE: Significantly Improved Brain MRI Results with DAC HYP versus Interferon in RRMS (2014) (0)
- IC-P2-083: Effects of actual and simulated Z-shifts on freesurfer-segmented whole-brain tissue, hippocampal, and lateral-ventricle volumes (2008) (0)
- 4-year follow-up of delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis (RRMS): integrated MRI outcomes from DEFINE, CONFIRM, and the ENDORSE extension study (2014) (0)
- Biomarkers in Pediatric Multiple Sclerosis: Predicting Recurrent Disease at the Initial Demyelinating Episode (2010) (0)
- Chapter 6. Use of Imaging in Multiple Sclerosis (2008) (0)
- Anti-MOG IgG1 Antibodies in Children (2019) (0)
- Peginterferon beta-1a reduces the number of black holes evolved from acute MRI lesions in newly diagnosed patients with relapsing-remitting multiple sclerosis: A post hoc analysis ADVANCE (2019) (0)
- Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis (S24.008) (2017) (0)
- Alemtuzumab Improves Clinical and Radiological Outcomes in Patients with Relapsing-remitting Multiple Sclerosis Over 8 Years: Care-MS I Follow-up (topaz Study) (2018) (0)
- Progressive retinal changes in pediatric multiple sclerosis. (2022) (0)
- Precision of Longitudinal Measures of Cortical Grey Matter Thickness Change and Ventricular Volume Change: Comparison to the Difference of Cross-Sectional Measures, Using Multicenter Scan-Reposition-Rescan MRI Data (2010) (0)
- Late Breaking News (2015) (0)
- Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial (2022) (0)
- Robust fusion of Jacobian maps for Deformation-Based Morphometry (2011) (0)
- Nonlinear Normalization of Magnetization Transfer Ratio Images for Multi-Centre Clinical Trials (2012) (0)
- R E V I E W A R T I C L E 1 H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review (2005) (0)
- Evobrutinib reduces volume of slowly expanding lesions (2022) (0)
- Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis Over 48 Weeks: A Randomized, Placebo-Controlled, Phase 2 Study (2020) (0)
- 31P-NMR studies in patients with exertional muscle pain syndrome (EMPS) responding to verapamil. (1987) (0)
- Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension (S16.008) (2023) (0)
- The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics (P6.344) (2017) (0)
- Poster 271 Post‐Poliomyelitis Syndrome Is Not Associated With Brain Atrophy (2012) (0)
- ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS (2016) (0)
- Single-timepoint low-dimensional characterization and classification of acute versus chronic multiple sclerosis lesions using machine learning (2022) (0)
- Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis (1337) (2020) (0)
- T-cell antigens in pediatric-onset multiple sclerosis: A unique window into early disease mechanisms (2017) (0)
- Adverse early life events are not associated with pediatric multiple sclerosis (MS) (P3.217) (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Douglas L Arnold?
Douglas L Arnold is affiliated with the following schools: